Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal…Read More
You might also be interested in reading US Treasury sanctions 5 crypto addresses connected to Russian neo-Nazi paramilitary group.